Read the stories of CAR-T patients from around the world
The Emily Whitehead Foundation
The Emily Whitehead Foundation is a non-profit that raises awareness and funds for childhood cancer research. Emily Whitehead is a three-time cancer survivor and was the first child in the world to receive CAR-T cell therapy, a form of immunotherapy. Emily is now five years cancer free. The Emily Whitehead Foundation aims to provide funding to researchers to develop innovative and less toxic treatments, such as immunotherapy, for pediatric cancer patients. Co-founders Tom and Kari Whitehead share Emily’s story to inspire others to take action in the fight to cure childhood cancer.
For more information, please visit www.emilywhiteheadfoundation.org
Our sincerest condolences go out to Nicole’s family and friends, as sadly she lost her fight against cancer.
Nicole began fighting for CAR T-Cell treatment in 2014 and it took over two years and half-a-dozen “no’s” before she was treated.
The last seven years has been a long battle full of challenge, risk, self advocacy, and research. Over the course of six years (2010 – 2016), she have had six relapses and have participated in three clinical trials (two at Stanford and one at UPenn). Her last clinical trial at The University of Pennsylvania (CAR T-Cell – Novartis CTL019) saved her life, and in October of 2016, she became a seven-time cancer survivor.
For further information, please visit www.nicolegularte.wordpress.com/2016/04/26/cancer-the-future-immunotherapy/
Our deepest sympathies are with the family and friends of Bradley Lowery, who has lost his battle with cancer.
Bradley was a terminally ill young football fan who had been taken under the wing of major players and was hoping to be given CAR-T therapy.
To learn more about Bradley and his fight click here https://bradleylowerysfight.org.uk/
Doug Olson, was diagnosed with chronic lymphocytic leukemia (CLL) in 1996.
For six years he endured what is known as “watch and wait” meaning he was not treated but was monitored frequently for signs that the cancer had advanced. After 6 years he had to undergo chemotherapy, followed by 5 years of remission. But in 2009 the cancer returned and this time he did not respond to treatment.
In September 2010, Olson became one of the first patients to undergo an experimental therapy known as CAR T-cell therapy, an innovative approach supported by funding from LLS.
Doug now wants to share his story to remind everyone that while breakthrough therapies are saving lives, work still needs to be done to find cures.